XML 74 R48.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Collaboration and Other Agreements, Incyte Corporation (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Oct. 31, 2017 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Jan. 01, 2018 performance_obligation
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  | $ 25,192 | $ 18,741 | $ 10,593 | $ 9,662 | $ 15,794 | $ 20,798 | $ 18,834 | $ 4,695 | $ 64,188 | $ 60,121 | $ 157,742 |
Incyte MGA012 Agreement | Incyte Corporation (Incyte) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  |  |  |  |  |  |  |  |  | $ 150,000 |
Amounts recognized |  |  |  |  |  |  |  |  |  |  | 15,000 |  |
Number of performance obligations | performance_obligation |  |  |  |  |  |  |  |  |  |  |  |  | 2
Transaction price | $ 154,000 |  |  |  |  |  |  |  |  |  |  |  |
Clinical trial activities selling price amount |  |  |  |  |  |  |  |  |  |  | 4,000 |  |
Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and regulatory milestone payments | 420,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential commercial milestone payments | $ 330,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from royalties percent | 24.00% |  |  |  |  |  |  |  |  |  |  |  |
Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from royalties percent | 15.00% |  |  |  |  |  |  |  |  |  |  |  |
Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  | 100 | 18,800 |  |
Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  | $ 22,100 | $ 22,200 |  |

X
- Definition Collaborative Agreement Transaction Price + References No definition available. + Details
Name: | mgnx_CollaborativeAgreementTransactionPrice
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development And Regulatory Milestone Payments Under Agreement, Recognized + References No definition available. + Details
Name: | mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial fee received from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Performance Obligations + References No definition available. + Details
Name: | mgnx_NumberOfPerformanceObligations
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential Commercial Milestone Payments Under Agreement + References No definition available. + Details
Name: | mgnx_PotentialCommercialMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Development and Regulatory Milestone Payments Under Agreement + References No definition available. + Details
Name: | mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Proceeds from Royalties, Percent + References No definition available. + Details
Name: | mgnx_ProceedsfromRoyaltiesPercent
Namespace Prefix: | mgnx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount + References No definition available. + Details
Name: | mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |